QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
held its Annual Meeting of Stockholders at 8:30 a.m. local time at
the San Diego Marriott Del Mar, 11966 El Camino Real, San Diego,
California 92037. The following matters were voted upon at the
meeting:
Directors as set forth below:
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Thomas D. Brown
|
29,272,632
|
378,664
|
2,120,722
|
|
Douglas C. Bryant
|
29,272,156
|
379,140
|
2,120,722
|
|
Kenneth F. Buechler
|
29,263,614
|
387,682
|
2,120,722
|
|
Mary Lake Polan
|
29,250,125
|
401,171
|
2,120,722
|
|
Jack W. Schuler
|
29,252,453
|
398,843
|
2,120,722
|
|
Charles P. Slacik
|
29,273,677
|
377,619
|
2,120,722
|
|
Kenneth J. Widder
|
28,917,899
|
733,397
|
2,120,722
|
LLP as the Companys independent registered public accounting firm
for the Company’s 2017 fiscal year by the votes set forth in the
table below:
|
Votes For
|
Votes Against
|
Abstentions
|
|
|
31,562,413
|
187,893
|
21,712
|
|
compensation of the Companys named executive officers by the votes
set forth in the table below:
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
29,508,849
|
87,189
|
55,258
|
2,120,722
|
of future advisory votes on executive compensation as follows:
|
Three Years
|
Two Years
|
One Year
|
Abstentions
|
Broker Non-Votes
|
|
1,698,165
|
9,167
|
27,910,830
|
33,134
|
2,120,722
|
board of directors of the Company has determined that the Company
will continue to hold future stockholder advisory votes on the
compensation of the Companys named executive officers every year.
The next advisory vote on the frequency of future stockholder
advisory votes on the compensation of the Companys named
executive officers will take place no later than at the Companys
2023 annual meeting of stockholders.
announcing the completion of its acquisition of the InflammaDry and
AdenoPlus eye-health businesses from RPS Diagnostics for
approximately $14 million in cash. Quidel anticipates initial
annualized revenues of approximately $4 to $5 million for these
eye-health businesses upon transition of the businesses to Quidel.
A copy of the press release is attached as Exhibit 99.1 to this
current report on Form 8-K.
exhibit attached hereto, is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of such
section. The information in this current report on Form 8-K shall
not be incorporated by reference into any
1933, as amended, except as expressly set forth by specific
reference in such filing.
forth in this Form 8-K reflect the Companys preliminary estimates
and are subject to change. You are cautioned not to place undue
reliance on these forward-looking statements, which reflect
managements analysis only as of the date of this Form 8-K. We
undertake no obligation to publicly release the results of any
revision or update of the forward-looking statements, except as
required by law.
|
|
|
|
|
|
|
|
(d) Exhibits.
|
|||
|
|
The following exhibit is furnished with this current
report on Form 8-K: |
|||
|
|
|
|||
|
Exhibit Number
|
Description of Exhibit
|
|||
|
|
|
|
|
|
|
99.1
|
Press release, dated May 16, 2017, announcing the
completion of the Company’s acquisition of the InflammaDry and AdenoPlus eye-health businesses from RPS Diagnostics. |
|||
|
|
|
|
|
|
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session down -0.02 at 24.80 with 146,375 shares trading hands.
